Table 1 Patient demographics and background disease characteristics
IL28B rs12979860 genotype | ||||
|---|---|---|---|---|
CC (n = 978) | CT (n = 1518) | TT (n = 420) | P valuee | |
Mean age, years ± SD | 46.8 ± 13.6 | 47.3 ± 13.2 | 46.8 ± 12.6 | 0.6973e |
G1 (n = 1702) | 47.9 ± 13.3 | 48.5 ± 13.2 | 48.1 ± 12.2 | 0.6602e |
G2 (n = 323) | 54.7 ± 13.1 | 55.1 ± 12.6 | 51.1 ± 15.9 | 0.5182e |
G3 (n = 574) | 39.2 ± 9.8 | 39.6 ± 10.3 | 39.0 ± 9.4 | 0.6864e |
G4 (n = 260) | 45.5 ± 13.2 | 44.3 ± 10.2 | 46.0 ± 10.4 | 0.7789e |
Male, n (%) | 582 (59.5) | 802 (52.8) | 224 (53.3) | 0.0049f |
Ethnic origin, n (%) | <0.0001g | |||
Asian | 89 (9.1) | 83 (5.5) | 9 (2.1) | |
Black | 5 (0.5) | 24 (1.6) | 19 (4.5) | |
Caucasian | 860 (87.9) | 1349 (88.9) | 373 (88.8) | |
Othera | 24 (2.5) | 62 (4.1) | 19 (4.5) | |
Region, n (%) | <0.0001g | |||
Asia | 78 (8.0) | 66 (4.3) | 8 (1.9) | |
Europe | 721 (73.7) | 1095 (72.1) | 303 (72.1) | |
Middle East | 138 (14.1) | 272 (17.9) | 75 (17.9) | |
Latin America | 41 (4.2) | 85 (5.6) | 34 (8.1) | |
BMI, kg/m2, mean ± SD | 25.8 ± 4.4 | 26.0 ± 4.5 | 26.0 ± 4.7 | 0.2617e |
HCV genotype, n (%) | <0.0001g | |||
Known genotype | 957 (97.9) | 1501 (98.9) | 414 (98.6) | |
G1b | 500 (52.2) | 930 (62.0) | 272 (65.7) | |
G2b | 126 (13.2) | 160 (10.7) | 37 (8.9) | |
G3b | 232 (24.2) | 277 (18.5) | 65 (15.7) | |
G4b | 92 (9.6) | 129 (8.6) | 39 (9.4) | |
G5/6b | 7 (0.7) | 5 (0.3) | 1 (0.2) | |
Unknown/missing | 21 (2.1) | 17 (1.1) | 6 (1.4) | |
Duration of HCV infection, mean years ± SD | 14.0 ± 12.3 | 14.0 ± 12.6 | 13.0 ± 12.4 | 0.1860e |
G1 (n = 1615) | 14.8 ± 13.1 | 14.5 ± 13.0 | 12.7 ± 12.5 | 0.0536e |
G2 (n = 303) | 16.6 ± 12.9 | 15.9 ± 13.5 | 16.6 ± 15.8 | 0.5129e |
G3 (n = 552) | 10.9 ± 9.6 | 11.8 ± 10.7 | 11.3 ± 8.5 | 0.4443e |
G4 (n = 249) | 13.7 ± 10.6 | 13.1 ± 10.4 | 14.8 ± 13.8 | 0.9733e |
HIV–HCV co-infection, n (%) | 38 (3.9) | 49 (3.2) | 15 (3.6) | 0.6000f |
Autoimmune disease, n (%) | 23 (2.4) | 46 (3.0) | 6 (1.4) | 0.6433f |
Liver disease other than CHC, n (%) | 34 (3.5) | 35 (2.3) | 13 (3.1) | 0.3728f |
Glucose intolerance/diabetes, n (%) | 73 (7.5) | 125 (8.2) | 33 (7.9) | 0.6614f |
Alcohol consumption, mean units/week ± SD | 1.83 ± 8.7 | 1.10 ± 5.2 | 0.87 ± 3.5 | 0.1423e |
Previous/current drug use/methadone or substitute therapy, n (%) | 289 (29.6) | 361 (23.8) | 96 (22.9) | 0.0013f |
Smoking, n (%)b | 0.0070g | |||
Never | 496 (50.9) | 887 (58.5) | 230 (54.9) | |
Previous | 141 (14.5) | 192 (12.7) | 56 (13.4) | |
Current | 338 (34.7) | 438 (28.9) | 133 (31.7) | |
ITPA rs1127354, CC, n (%) | 818 (83.6) | 1338 (88.1) | 372 (88.6) | 0.0020f |
ITPA rs7270101, AA, n (%) | 793 (81.1) | 1254 (82.6) | 342 (81.4) | 0.6563f |
Mean ALT, IU/L ± SD | 104.1 ± 103.5 | 83.4 ± 79.2 | 72.9 ± 63.8 | <0.0001e |
Mean ALT ratio ± SDc | 2.28 ± 2.07 | 1.88 ± 1.55 | 1.65 ± 1.31 | <0.0001e |
G1 (n = 1671) | 2.09 ± 1.94 | 1.77 ± 1.38 | 1.63 ± 1.30 | 0.0007e |
G2 (n = 312) | 2.42 ± 2.58 | 1.96 ± 1.96 | 1.21 ± 0.829 | 0.0061e |
G3 (n = 565) | 2.80 ± 2.15 | 2.32 ± 1.91 | 2.05 ± 1.62 | <0.0001e |
G4 (n = 247) | 2.00 ± 1.75 | 1.66 ± 1.11 | 1.65 ± 1.09 | 0.3885e |
Mean HCV RNA, log10 IU/mL ± SD | 5.94 ± 0.99 | 5.83 ± 0.81 | 5.68 ± 0.83 | <0.0001e |
HCV RNA > 800,000 IU/mL, n (%)bd | 607/959 (63.3) | 764/1498 (51.0) | 179/416 (43.0) | <0.0001f |
G1 | 320/495 (64.6) | 493/921 (53.5) | 116/268 (43.3) | <0.0001f |
G2 | 81/124 (65.3) | 80/157 (51.0) | 23/37 (62.2) | 0.1853 |
G3 | 152/231 (65.8) | 131/276 (47.5) | 22/65 (33.8) | <0.0001 |
G4 | 44/92 (47.8) | 53/128 (41.4) | 14/39 (35.9) | 0.1792 |
Assessment of cirrhosis, n (%) | 0.0723g | |||
Biopsy | 295 (30.2) | 419 (27.6) | 114 (27.1) | |
Noninvasive | 646 (66.0) | 1046 (68.9) | 289 (68.8) | |
Both | 37 (3.8) | 46 (3.0) | 12 (2.9) | |
None | 1 (0.1) | 7 (0.5) | 5 (1.2) | |
Fibrosis stage (biopsy or noninvasive), n (%) | ||||
Assessment made | 976 (99.8) | 1511 (99.5) | 415 (98.8) | |
Cirrhosis/transition to cirrhosisb | 248 (25.4) | 390 (25.8) | 119 (28.7) | 0.2702f |
No cirrhosisb | 728 (74.6) | 1121 (74.2) | 296 (71.3) | |
Missing | 2 (0.2) | 7 (0.5) | 5 (1.2) | |